Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients: High-Dose drug combo tested after first treatment fails

NCT ID NCT06652048

Recruiting now Disease control Sponsor: Jialei Wang Source: ClinicalTrials.gov ↗

First seen Nov 21, 2025 · Last updated May 15, 2026 · Updated 20 times

Summary

This study is for people with advanced non-small cell lung cancer that has a specific gene mutation (EGFR) and has gotten worse after first-line treatment with a third-generation EGFR-TKI drug. The trial will test whether taking a higher dose of the drug furmonertinib, either alone or combined with chemotherapy, can help control the cancer longer. About 60 participants will be randomly assigned to one of three treatment groups and followed until their disease progresses or side effects become too severe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fudan university shanghai cancer center

    RECRUITING

    Shanghai, Shanghai Municipality, 021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER